Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1179-1187

  Engels, Eric A ^a   Lau, Joseph ^a   Barza, Michael ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CIPROFLOXACIN; CLOTRIMAZOLE; COTRIMOXAZOLE; ENOXACIN; GRANULOCYTE COLONY STIMULATING FACTOR; NORFLOXACIN; NYSTATIN; OFLOXACIN; PEFLOXACIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CANCER MORTALITY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031934038     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1179     Document Type: Article

References (50)

1. Dekker AW, Rozenberg-Arska M, Sixma JJ, et al: Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med 95:555-559, 1981
2. Lew MA, Kehoe K, Ritz J, et al: Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 51:630-636, 1991
3. Casali A, Verri C, Paoletti G, et al: Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. Chemioterapia 7:327-329, 1988
4. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328-340, 1966
5. Bodey GP, Rodriguez V, Chang HY, et al: Fever and infection in leukemic patients: A study of 494 consecutive patients. Cancer 41:1610-1622, 1978
6. Del Favero A, Menichetti F: The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients [review]. Eur J Cancer 29A:S2-S6, 1993
7. Young LS: The new fluorinated quinolones for infection prevention in acute leukemia. Ann Intern Med 106:144-146, 1987 (editorial)
8. Hooper DC: Quinolones, in Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases (ed 4). New York, NY, Churchill Livingstone, 1995, pp 364-376
9. Maiche AG, Muhonen T: Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer 29A: 1403-1405, 1993
10. Brodsky AL, Minissale CJ, Melero MJ, et al: Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (Buenos Aires) 53:401-407, 1993
11. Talbot GH, Cassileth PA, Paradiso L, et al: Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. Antimicrob Agents Chemother 37:474-482, 1993
12. Karp JE, Merz WG, Hendricksen C, et al: Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106:1-7, 1987
13. Sampi K, Maseki N, Hattori M: A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: A randomized study. Gan Kagaku Ryoho 19:823-826, 1992
14. Yamada T, Dan K, Nomura T: Prevention of bacterial and fungal infections in acute leukemia patients: A new and potent combination of oral norfloxacin and amphotericin B. Intern Med 32:710-715, 1993
15. Hartlapp JH: Antimicrobial prophylaxis in immunocompromised patients. Drugs 34:131-133, 1987
16. Bow EJ, Rayner E, Louie TJ: Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The tradeoff for reduced gram-negative sepsis. Am J Med 84:847-854, 1988
17. Cruciani M, Concia E, Navarra A, et al: Prophylactic cotrimoxazole versus norfloxacin in neutropenic children - Perspective randomized study. Infection 17:65-69, 1989
18. Lew MA, Kehoe K, Ritz J, et al: Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial. J Clin Oncol 13:239-250, 1995
19. Winston DJ, Ho WG, Champlin RE, et al: Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med 82:40-46, 1987
20. Orlandi E, Navarra A, Cruciani M, et al: Norfloxacin versus cotrimoxazole for infection prophylaxis in granulocytopenic patients with acute leukemia. A prospective randomized study. Haematologica 75:296-298, 1990
21. Liang RHS, Yung RWH, Chan TK, et al: Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 34:215-218, 1990
22. Fanci RM, Bosi A, Longo G, et al: Ofloxacin versus cotrimoxazole for prevention of infections in granulocytopenic patients. Rev Esp Quimioterap 2:335-340, 1989
23. Kern W, Kurrle E: Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection 19:73-80, 1991
24. Mocikova K, Svac J, Faber E, et al: Comparison of tarivid and biseptol in the prevention of bacterial infections in patients with acute leukemia. Vnitrni Lekarstvi 38:166-172, 1992
25. Gualtieri RJ, Donowitz GR, Kaiser DL, et al: Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 74:934-940, 1983
26. Cruciani M, Rampazzo R, Malena M, et al: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 23:795-805, 1996
27. Hogg RV, Tanis EA: Probability and Statistical Inference (ed 2). New York, NY, Macmillan, 1983
28. Ioannidis JPA, Cappelleri JC, Lau J, et al: Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: A meta-analysis. Ann Intern Med 122:856-866, 1995
29. Laird NM, Mosteller F: Some statistical methods for combining experimental results. Int J Tech Assess Health Care 6:5-30, 1990
30. Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1-30, 1987
31. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989
32. Schulz KF, Chalmers I, Hayes RJ, et al: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412, 1995
33. Schimpff SC: Infections in the cancer patient - Diagnosis, prevention, and treatment, in Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases (ed 4). New York, NY, Churchill Livingstone, 1995, pp 2666-2750
34. Van der Waaij D, Berghuis JM, Lekkerkerk JEC: Colonization resistance of the digestive tract of mice during systemic antibiotic treatment. J Hyg (Cambridge) 70:605-610, 1972
35. Winston DJ, Ho WG, Nakao SL, et al: Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 80:884-890, 1986
36. Winston DJ, Ho WG, Bruckner DA, et al: Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 88:36-42, 1990
37. Kern WV, Andriof E, Oethinger M, et al: Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681-687, 1994
38. Carratala J, Fernandez-Sevilla A, Tubau F, et al: Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557-560, 1995
39. Oppenheim BA, Hartley JW, Lee W, et al: Outbreak of coagulase negative staphylococcus highly resistant to ciproftoxacin in a leukaemia unit. Br Med J 299:294-297, 1989
40. D'Antonio D, Iacone A, Fioritoni G, et al: Antibacterial prophylaxis in granulocytopenic patients: A randomized study of oftoxacin versus norfloxacin. Curr Ther Res 50:304-311, 1991
41. Bow EJ, Mandell LA, Louie TJ, et al: Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 125:183-190, 1996
42. The GIMEMA Infection Program: Prevention of bacterial infection in neutropenic patients with hematologic malignancies: A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 115:7-12, 1991
43. Weiser B, Lange M, Fialk MA, et al: Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: A controlled trial. Ann Intern Med 95:436-438, 1981
44. Gurwith MJ, Brunton JL, Lank BA, et al: A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 66:248-256, 1979
45. Huovinen P, Sundstrom L, Swedberg G, et al: Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 39:279-289, 1995
46. Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276:637-639, 1996
47. Verhoef J: Prevention of infections in the neutropenic patient [review]. Clin Infect Dis 17:S359-S367, 1993
48. Broun ER, Wheat JL, Kneebone PH, et al: Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob Agents Chemother 38:576-579, 1994
49. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer: Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. JAMA 272:1183-1189, 1994
50. Bow EJ, Loewen R, Vaughan D: Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 20:907-912, 1995